Al-Khatib, S. M., Mulder, H., Wojdyla, D., Lopes, R. D., Wallentin, L., Alexander, J. H., … Granger, C. B. (2021). Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. Circ Arrhythm Electrophysiol, 14(3), e009614. https://doi.org/10.1161/CIRCEP.120.009614

Al-Khatib, Sana M., Hillary Mulder, Daniel Wojdyla, Renato D. Lopes, Lars Wallentin, John H. Alexander, Ziad Hijazi, Shinya Goto, and Christopher B. Granger. “Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial.” Circ Arrhythm Electrophysiol 14, no. 3 (March 2021): e009614. https://doi.org/10.1161/CIRCEP.120.009614.

Al-Khatib SM, Mulder H, Wojdyla D, Lopes RD, Wallentin L, Alexander JH, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. Circ Arrhythm Electrophysiol. 2021 Mar;14(3):e009614.

Al-Khatib, Sana M., et al. “Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial.” Circ Arrhythm Electrophysiol, vol. 14, no. 3, Mar. 2021, p. e009614. Pubmed, doi:10.1161/CIRCEP.120.009614.

Al-Khatib SM, Mulder H, Wojdyla D, Lopes RD, Wallentin L, Alexander JH, Hijazi Z, Goto S, Granger CB. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. Circ Arrhythm Electrophysiol. 2021 Mar;14(3):e009614.